Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Pyxis Oncology, Inc. (PYXS)
P/E ratio as of 2023: -0.97
According to Pyxis Oncology, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.97. At the end of 2022 the company had a P/E ratio of -0.38.
P/E ratio history for Pyxis Oncology, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.97 |
| 2022 | -0.38 |
| 2021 | -4.34 |
| 2020 | -35.49 |
| 2019 | -169.94 |